መነሻ › ዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ
በአሜሪካ ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ ተሳታፊዎችን እየፈለጉ ያሉ ክሊኒካዊ ጥናቶች
ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ የሚደረጉ 101 ጥናቶች በአሜሪካ ውስጥ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በጣም ብዙ ጥናቶች ያሏቸው ከተሞች
- New York City, NY21 ጥናቶች
- Baldwin Park, CA19 ጥናቶች
- Chicago, IL18 ጥናቶች
- Los Angeles, CA17 ጥናቶች
- Houston, TX17 ጥናቶች
- Boston, MA16 ጥናቶች
- Milwaukee, WI16 ጥናቶች
- Portland, OR15 ጥናቶች
- Nashville, TN15 ጥናቶች
- Philadelphia, PA15 ጥናቶች
- Durham, NC14 ጥናቶች
- Dallas, TX13 ጥናቶች
- Seattle, WA12 ጥናቶች
- Washington, DC12 ጥናቶች
- Salt Lake City, UT12 ጥናቶች
- Denver, CO11 ጥናቶች
- Cleveland, OH11 ጥናቶች
- Cincinnati, OH11 ጥናቶች
- Rochester, MN10 ጥናቶች
- Atlanta, GA10 ጥናቶች
- Richmond, VA10 ጥናቶች
- Columbus, OH9 ጥናቶች
- Edison, NJ9 ጥናቶች
- Omaha, NE9 ጥናቶች
- Cedar Rapids, IA9 ጥናቶች
- San Antonio, TX8 ጥናቶች
- Sacramento, CA8 ጥናቶች
- Greenburgh, NY8 ጥናቶች
- Jacksonville, FL8 ጥናቶች
- Louisville, KY8 ጥናቶች
- San Francisco, CA8 ጥናቶች
- St. Louis, MO8 ጥናቶች
- New Haven, CT8 ጥናቶች
- Grand Rapids, MI8 ጥናቶች
- Charlottesville, VA7 ጥናቶች
- Miami, FL7 ጥናቶች
- Indianapolis, IN7 ጥናቶች
- Kansas City, MO7 ጥናቶች
- Aurora, CO7 ጥናቶች
- Pittsburgh, PA6 ጥናቶች
በክልል
- New Jersey13 ጥናቶች
- New Mexico3 ጥናቶች
- New York31 ጥናቶች
- North Carolina20 ጥናቶች
- North Dakota4 ጥናቶች
- Ohio23 ጥናቶች
- Oklahoma5 ጥናቶች
- Oregon15 ጥናቶች
- Pennsylvania19 ጥናቶች
- South Carolina4 ጥናቶች
- South Dakota3 ጥናቶች
- Tennessee19 ጥናቶች
- Texas29 ጥናቶች
- Utah14 ጥናቶች
- Virginia17 ጥናቶች
- Washington17 ጥናቶች
- Wisconsin19 ጥናቶች
- ሉዊዚያና6 ጥናቶች
- ሚሺጋን15 ጥናቶች
- ሚኔሶታ16 ጥናቶች
- ሚዙሪ8 ጥናቶች
- ማሳቹሴትስ16 ጥናቶች
- ሜሪላንድ13 ጥናቶች
- ሞንታና4 ጥናቶች
- ኒብራስካ9 ጥናቶች
- ኔቫዳ3 ጥናቶች
- አላባማ4 ጥናቶች
- አሪዞና13 ጥናቶች
- አርካንሳስ4 ጥናቶች
- አይዳሆ4 ጥናቶች
- አዮዋ11 ጥናቶች
- ኢሊኖይ22 ጥናቶች
- ኢንዲያና9 ጥናቶች
- ከንታኪ11 ጥናቶች
- ካሊፎርኒያ42 ጥናቶች
- ካንሳስ7 ጥናቶች
- ኮሎራዶ19 ጥናቶች
- ኮነቲከት8 ጥናቶች
- ዲስትሪክት ኦፍ ኮሎምቢያ4 ጥናቶች
- ጆርጂያ15 ጥናቶች
- ፍሎሪዳ23 ጥናቶች
በቅርብ ጊዜ የተዘመኑ ጥናቶች
Official study text (English)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06863402Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06834373Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07763210Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06649812Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ65 እስከ 99 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06091865A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06890884Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
6 Months – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT05272384ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።